Pinocembrin inhibits angiotensin II-induced vasoconstriction via suppression of the increase of [Ca2+]i and ERK1/2 activation through blocking AT1R in the rat aorta

Biochemical and Biophysical Research Communications

Volumn 435, Issue 1, 2013, Pages 69-75

  Li, Li ^a   Pang, Xiao Bin ^a   Chen, Bai Nian ^a   Gao, Li ^a   Wang, Le ^a   Wang, Shou Bao ^a   Wang, Su Bo ^a   Liu, De Pei ^b   Du, Guan Hua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Ca2+ i; Angiotensin II; AT1R; ERK1 2; Pinocembrin; Vasoconstriction

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN TYPE 1 RECEPTOR; CALCIUM ION; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN LIGHT CHAIN 2; PINOCEMBRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONCENTRATION (PARAMETERS); DRUG MECHANISM; ENZYME REGULATION; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; BLOTTING, WESTERN; CALCIUM; CARDIAC MYOSINS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVANONES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; VASOCONSTRICTION;

RATTUS;

EID: 84878195493     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.039     Document Type: Article

References (28)

1. Calderone V., Chericoni S., Martinelli C., Testai L., Nardi A., Morelli I., Breschi M.C., Martinotti E. Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370:290-298.
2. Liu R., Gao M., Yang Z.H., Du G.H. Pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro. Brain Res. 2008, 1216:104-115.
3. Sala A., Recio M.C., Schinella G.R., Manez S., Giner R.M., Cerda-Nicolas M., Rosi J.L. Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside. Eur. J. Pharmacol. 2003, 461:53-61.
4. Uzel A., Sorkun K., Oncag O., Cogulu D., Gencay O., Salih B. Chemical compositions and antimicrobial activities of four different Anatolian propolis samples. Microbiol. Res. 2005, 160:189-195.
5. Zhu X.M., Fang L.H., Li Y.J., Du G.H. Endothelium-dependent and -independent relaxation induced by pinocembrin in rat aortic rings. Vascul. Pharmacol. 2007, 46:160-165.
6. Shi L.L., Chen B.N., Gao M., Zhang H.A., Li Y.J., Wang L., Du G.H. The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats. Life Sci. 2011, 88:521-528.
7. Touyz R.M. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr. Hypertens. Rep. 2003, 5:155-164.
8. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007, 292:C82-97.
9. Inaba S., Iwai M., Tomono Y., Senba I., Furuno M., Kanno H., Okayama H., Mogi M., Higaki J., Horiuchi M. Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes. Stroke 2009, 40:597-603.
10. Saavedra J.M., Benicky J., Zhou J. Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT(1) Receptor Antagonists in the Brain. Cell Mol. Neurobiol. 2006, 26:1097-1109.
11. Walther T., Olah L., Harms C., Maul B., Bader M., Hortnagl H., Schultheiss H.P., Mies G. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J. 2002, 16:169-176.
12. Gao M., Liu R., Zhu S.Y., Du G.H. Acute neurovascular unit protective action of pinocembrin against permanent cerebral ischemia in rats. J. Asian Nat. Prod. Res. 2008, 10:551-558.
13. Meng F., Liu R., Gao M., Wang Y., Yu X., Xuan Z., Sun J., Yang F., Wu C., Du G. Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats. Brain Res. 2011, 1391:93-101.
14. Engelhorn T., Goerike S., Doerfler A., Okorn C., Forsting M., Heusch G., Schulz R. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 2004, 24:467-474.
15. Ito T., Yamakawa H., Bregonzio C., Terron J.A., Falcon-Neri A., Saavedra J.M. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002, 33:2297-2303.
16. Gao M., Zhang W.C., Liu Q.S., Hu J.J., Liu G.T., Du G.H. Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio. Eur. J. Pharmacol. 2008, 591:73-79.
17. Tuccinardi T., Martinelli A. Computational approaches on angiotensin receptors and their ligands: recent developments and results. Curr. Med. Chem. 2007, 14:3105-3121.
18. Evans J.F., Lee J.H., Ragolia L. Ang-II-induced Ca(2+) influx is mediated by the 1/4/5 subgroup of the transient receptor potential proteins in cultured aortic smooth muscle cells from diabetic Goto-Kakizaki rats. Mol. Cell Endocrinol. 2009, 302:49-57.
19. Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260:3440-3450.
20. Wynne B.M., Chiao C.W., Webb R.C. Vascular Smooth Muscle Cell Signaling Mechanisms for Contraction to Angiotensin II and Endothelin-1. J. Am. Soc. Hypertens. 2009, 3:84-95.
21. Aulakh G.K., Sodhi R.K., Singh M. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci. 2007, 81:615-639.
22. Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?. Am. J. Cardiol. 1999, 84:9S-15S.
23. Naik P., Murumkar P., Giridhar R., Yadav M.R. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists-a perspective. Bioorg. Med. Chem. 2010, 18:8418-8456.
24. Hosomi N., Nishiyama A., Ban C.R., Naya T., Takahashi T., Kohno M., Koziol J.A. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005, 134:225-231.
25. Berridge M.J. Smooth muscle cell calcium activation mechanisms. J. Physiol. 2008, 586:5047-5061.
26. Touyz R.M., Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 2000, 52:639-672.
27. Nguyen Dinh Cat A., Touyz R.M. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr. Hypertens. Rep. 2011, 13:122-128.
28. Zhou C.H., Qian Z.Y., Xiang M., He S.Y. Involvement of Ca2+ in the inhibition by crocetin of angiotensin II-induced ERK1/2 activation in vascular smooth muscle cells. Eur. J. Pharmacol. 2007, 554:85-91.